Hanley DF, et al. - In this randomized, controlled, open-label, blinded endpoint phase 3 trial done at 78 hospitals in the USA, Canada, Europe, Australia, and Asia, researchers evaluated the efficiency and safety of minimally invasive surgery with thrombolysis in intracerebral hemorrhage evacuation (MISTIE III) between Dec 30, 2013, and Aug 15, 2017. They found a similar number of subjects with symptomatic bleeding and brain bacterial infections between the MISTIE and standard medical care groups. They did not observe any improvement/good response 365 days after intracerebral hemorrhage (moderate to large intracerebral).